CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study

CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study

Abstract Introduction A 27-week analysis of this phase 3 study demonstrated the interchangeability of the adalimumab biosimilar CT-P17 and reference adalimumab. The current 52-week analysis reports secondary data from the open-label extension period (OLE) of the study. Methods In this randomized, do...

Full description

Saved in:
Bibliographic Details
Main Authors: David M. Pariser, Mark G. Lebwohl, Janusz Jaworski, Jakub Trefler, Stefan Daniluk, Anna Dudek, Wojciech Baran, Witold Owczarek, Pawel Brzewski, Mariusz Sikora, Marek Krogulec, SungHyun Kim, JeeHye Suh, EunJin Choi, JungBin Cha, HyunJin Lee, SungJeong Lee, John Y. Koo
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-03-01
Series:Dermatology and Therapy
Subjects:
Adalimumab
Biosimilar
CT-P17
Interchangeability
Psoriasis
Switching
Online Access:https://doi.org/10.1007/s13555-025-01383-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-025-01383-5

Similar Items